Novocure Inc.

Portsmouth, NH

UEI
P3S3GK3DTUA8
CAGE
81PZ6
Primary NAICS
334510 Electromedical and Electrotherapeutic Apparatus Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Foreign Owned
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
195 Commerce Way, Portsmouth, NH 03801, USA
Website
novocure.com
Founded
2000
Employees
1K-5K
Estimated annual revenue
$500M-$1B
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $646,769
FY2026 $11,904,192
FY2025 $8,102,997
FY2024 $8,784,095
FY2023 $6,439,457

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Department of Veterans Affairs $12,550,962

Contract vehicles

Contract awards

Award Agency Obligated Awarded
Pros-transducers 36C25927F0052 Veterans Integrated Service Network 19 (VHA) $99,497
Transducer device 36C24627N0288 Veterans Integrated Service Network 6 (VHA) $49,749
Optune transducers 36C25027F0077 Veterans Integrated Service Network 10 (VHA) $49,749
Prosthetics - optune rental 36C26127N0173 Veterans Integrated Service Network 21 (VHA) $49,785
Optune plus transducer 36C26327N0209 Veterans Integrated Service Network 23 (VHA) $49,749

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

About the company

Novocure Inc., a foreign-owned medical device manufacturer based in Portsmouth, New Hampshire, supplies Optune Tumor Treating Fields (TTFields) cancer therapy transducers and devices to the Department of Veterans Affairs as a prime contractor exclusively, competing full-and-open with no set-asides. The company operates as a for-profit organization and the sole-source provider of its proprietary non-invasive oncology technology to the VA, delivering directly to VA medical facilities nationwide with no subcontractor involvement.

Novocure's federal footprint is narrow by geography but deep by customer concentration — nearly all 1,201 recent awards (100% prime) flow through a single vehicle: the GSA Medical Equipment and Supplies Federal Supply Schedule (FSS-65-II-A), a $28.85 million multiple-award contract established November 1, 2022, and running through October 31, 2027. Through this schedule, individual Veterans Integrated Service Networks issue firm fixed-price delivery orders and purchase orders ranging from approximately $16,600 to $99,500. Representative awards include a $49,748.73 delivery order from Veterans Integrated Service Network 1 in October 2026 for Optune Plus transducers (Portsmouth, NH delivery); a $99,497.46 order from VISN 17 in September 2026 for Optune Plus transducers (San Antonio, TX location); and a $49,748.73 delivery order from VISN 9 in September 2026 for Optune transducer rental prosthetics (terminal cancer treatment). All orders carry no set-aside designation and firm fixed-price terms.

Customer concentration is extreme and vertically distributed across VA medical networks. The top five VISNs by award count — VISN 10, 23, 20, 1, and 7 — account for 43% of recent awards but carry relatively modest dollar values ($2.4 million to $5.9 million combined per VISN). By contrast, VISN 12 anchors 63% of combined potential value across the top five customers with only 59 awards valued at $31.4 million — indicating substantially larger individual order values from that network. This divergence signals that individual VA facilities or programs within VISN 12 place considerably larger orders (likely multi-month rental arrangements or bulk transducer procurement) compared to the high-volume, smaller-value patterns of other networks. Novocure's entire active customer base is the VA's Veterans Health Administration, distributed across all 23 Veterans Integrated Service Networks nationwide.

Activity has grown modestly year over year, from 161 awards in 2022 to 229 in 2024, settling at 219 in 2026 (through October). Ninety-nine awards with combined potential value of $5.2 million are set to complete within the next twenty-four months and face recompete risk. The company's NAICS footprint is dominated by Electromedical and Electrotherapeutic Apparatus Manufacturing (788 awards) and Surgical Appliance and Supplies Manufacturing (353 awards), with PSC codes concentrated on Medical and Surgical Instruments, Equipment, and Supplies (1,085 awards). Novocure's capability is singular and proprietary: manufacturing and supplying FDA-approved Optune Tumor Treating Fields cancer therapy transducers and device systems for non-invasive treatment of glioblastoma and mesothelioma, with no diversification into other medical device categories or therapeutic areas visible in the award portfolio. Place of performance spans Portsmouth, New Hampshire as the primary manufacturing and coordination hub, with secondary performance dispersed across VA medical facility locations serving veteran populations nationwide. The vendor operates without competitors in its federal posture — Novocure holds de facto monopoly status as the sole-source provider of TTFields technology to the federal government, a position reinforced by the proprietary nature of its transducer technology and the absence of any set-aside or competitive vehicle designation across its awards.

Quick answers

Is Novocure Inc. registered in SAM.gov?

Yes. Novocure Inc.'s SAM.gov registration is active through June 19, 2027.

What is Novocure Inc.'s CAGE code?

Novocure Inc.'s CAGE code is 81PZ6, and its Unique Entity ID (UEI) is P3S3GK3DTUA8.

Which contract vehicles does Novocure Inc. hold?

Novocure Inc. holds a place on 1 federal contract vehicle: FSS-65-II-A.

How much has Novocure Inc. received in federal contracts?

Federal contracts obligated $8,102,997 to Novocure Inc. in fiscal year 2025 and $35,877,511 in fiscal years 2023 through 2027.

How does Novocure Inc. rank among federal contractors?

Novocure Inc. ranked #17 in PSC 6532, #17 in NAICS 334510 and #31 in PSC 6510 in FY2025.

What is Novocure Inc.'s most recent federal award?

Novocure Inc.'s most recent federal contract award is Pros-transducers (36C25927F0052), from Veterans Integrated Service Network 19 (VHA), on October 28, 2026.

On GovTribe

See Novocure Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Contract vehicles
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors

Find teaming partners on GovTribe